ArticleFrontiers in immunology2026
Unique B- and plasma cell signature differentiates hidradenitis suppurativa from psoriasis and atopic dermatitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hidradenitis suppurativa (HS), psoriasis (PsO), and atopic dermatitis (AD) have unique disease pathogenesis and distinct pathology, despite sharing some immunological pathways. This study aimed to evaluate the transcriptomic differences between HS, PsO, and AD lesions, which drive these unique pathogenic features. Methods: Bulk RNA sequencing was performed on 19 healthy controls (HC), 15 HS, 21 PsO, and 15 AD lesional skin samples. Results: PsO lesions were defined by a strong interleukin (IL)-17 signature, and AD lesions had increased T helper (Th2) signaling. HS lesions had a more heterogeneous inflammatory profile involving TNF, IL-17, B cells, and NLR signaling. Weighted gene coexpression network analysis identified T-cell signaling and epidermal development as important characteristics of PsO lesions, while HS lesions were defined by complement activation, B-cell signaling, and fibroblast-associated pathways consistent with potential scarring in HS. Finally, gene expression analysis identified increased expression of B-cell-, plasma cell-, and immunoglobulin-associated genes in HS lesions relative to HC skin, PsO, and AD lesions. Discussion: These data suggest that HS pathogenesis is more heterogeneous than AD or PsO and highlight an important role of B and plasma cells in HS inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.